

Philip G Humphreys

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6518091/publications.pdf>

Version: 2024-02-01

15
papers

669
citations

759233

12
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1053
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1425-1439.	6.4	177
2	Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. <i>ACS Chemical Biology</i> , 2018, 13, 2862-2867.	3.4	118
3	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 695-709.	6.4	70
4	Clinical progress and pharmacology of small molecule bromodomain inhibitors. <i>Current Opinion in Chemical Biology</i> , 2016, 33, 58-66.	6.1	69
5	Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 714-746.	6.4	45
6	Progress in the Development of non-BET Bromodomain Chemical Probes. <i>ChemMedChem</i> , 2016, 11, 477-487.	3.2	40
7	Advancements in the Development of non-BET Bromodomain Chemical Probes. <i>ChemMedChem</i> , 2019, 14, 362-385.	3.2	36
8	Alkene <i>anti</i> -Dihydroxylation with Malonoyl Peroxides. <i>Organic Letters</i> , 2015, 17, 5132-5135.	4.6	31
9	Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5816-5840.	6.4	21
10	BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2937-2957.	3.0	19
11	Fragment-Based Identification of Ligands for Bromodomain-Containing Factor 3 of <i>Trypanosoma cruzi</i> . <i>ACS Infectious Diseases</i> , 2021, 7, 2238-2249.	3.8	14
12	Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2262-2287.	6.4	14
13	Alkene <i>Syn</i> - and <i>Anti</i> -Oxyamination with Malonoyl Peroxides. <i>Organic Letters</i> , 2020, 22, 1659-1664.	4.6	8
14	Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1308-1317.	2.8	4
15	Small molecules and their role in effective preclinical target validation. <i>Future Medicinal Chemistry</i> , 2017, 9, 1579-1582.	2.3	3